乙型肝炎后肝硬化并发原发性肝癌患者 乙型肝炎病毒定量检测的临床意义

目的 探讨乙型肝炎后肝硬化并发原发性肝癌患者的乙型肝炎病毒指标定量检测的变化，以期 为乙型肝炎后肝癌的早期诊断提供临床指导意义。方法 采用回顾性分析方法，选取2015 年2 月—2016 年 2 月在华北理工大学附属医院及唐山市传染病医院住院的乙型肝炎后肝硬化并发肝癌的患者59 例，选择82 例同期住院的单纯乙型肝炎后肝硬化患者作为对照。分析两组乙肝病毒标志物HBsAg、HBsAb、HBeAg、 HBeAb、HBV DNA 的差异。结果 肝硬化并发肝癌组HBsAg、HBeAg 的含量低于单纯肝硬化组，差异有统 计学意义（P <0.05），两组患者HBsAb、HBeAb 及HBV DNA 的含量差异无统计学意义（P >0.05）。结论 随 着乙型肝炎后肝硬化病情的进展，HBsAg、HBeAg 含量可能会逐渐降低，但这并不意味着病情得到控制或好 转，有可能进展为肝癌，所以对病毒载量较低的乙型肝炎后肝硬化患者仍需积极抗病毒治疗，且应至少3 个月 复查1 次乙型肝炎病毒标志物定量检测，以提高早期肝癌的检出率。

Clinical significance of quantitative detection of hepatitis B virus in hepatitis B cirrhosis patients with primary liver cancer

Objective To investigate the clinical significance of quantification of hepatitis B virus in patients with primary liver cancer. Methods Totally 59 patients with primary liver complicated by hepatitis B cirrhosis as well as 82 patients with simple hepatitis B cirrhosis who were admitted into our hospital during February 2015 to February 2016 were enrolled in this study as observation group and control group, respectively. HBV markers including HBsAg, HBsAb, HBeAg, HBeAb, and HBV DNA were measured. Results The content of HBsAg and HBeAg in observation group was significantly decreased compapred with that in control group (P < 0.05). No obvious differences in HBsAb, HBeAb and HBV DNA were identified in two groups (P > 0.05). Conclusion Content of HBsAg and HBeAg may decrease along with the progression of hepatitis B cirrhosis, which may develop into liver cancer, however. Hepatitis B cirrhosis patients should continue on anti-virus treatment for further prevention of liver cancer.